Clinical Takeaway
In this phase 3 trial of 820 adults with chronic low back pain, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks with extended follow-up periods reaching up to one year. The trial design is rigorous, including a randomized withdrawal phase to assess durability of response. Results from this study carry meaningful weight for patients who have not responded adequately to conventional treatments.
#2 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by evaluating a cannabis-based therapeutic for chronic low back pain, a condition affecting over 500 million people globally where current pharmacologic options demonstrate limited efficacy and significant safety concerns. The large-scale, randomized, placebo-controlled design with extended follow-up provides robust evidence needed to inform clinical decision-making regarding cannabis extracts as a viable alternative to conventional analgesics and opioids. If efficacious and well-tolerated, VER-01 could substantially expand the therapeutic armamentarium for CLBP management and potentially reduce reliance on medications with higher abuse and adverse event profiles.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial presents encouraging data for full-spectrum cannabis extract in chronic low back pain, a condition where conventional pharmacotherapy often falls short, though several considerations warrant careful interpretation before clinical adoption. The study’s 12-week double-blind design with 820 participants provides a reasonably robust foundation, yet the incomplete abstract limits assessment of primary outcome magnitude, safety profiles across subgroups, and whether efficacy persists in the open-label extension phase, which can introduce bias. Clinicians should note that full-spectrum extracts contain variable cannabinoid and terpene ratios that may not be standardized across batches, potentially affecting reproducibility and individual patient response, and the study population’s demographic characteristics and concurrent medication use remain unclear from the information provided. Additionally, the mechanism by which cannabis addresses nociception in CLBP versus merely improving pain perception or mood requires clarification to guide appropriate patient selection. In practice, this trial suggests VER-01 may be a reasonable consideration for patients with inadequate response to or